 |
Quotes delayed 20 minutes
|
Strong Buy (3.57 out of 4)
68th percentile
|
|
|
 Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Thursday, December 12, 9:05 PM
Slide #46. Spero Therapeutics, Inc. — Preferred Stock Offering
| Company: |
Spero Therapeutics, Inc. (NASDAQ:SPRO) |
| Date announced: |
7/9/2018 |
| Shares Offered: |
3,780,000 |
| Date of Pricing: |
7/12/2018 |
| Price Per Share: |
$12.50 |
| Preferred Stock Offering Details: |
Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, today announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. All of the shares in the offering will be sold by Spero. In addition, Spero expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discount. -updated 7/12- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock. The public offering price of each share of common stock is $12.50 and the public offering price of each share of Series A Preferred Stock is $12,500.00. The gross proceeds to Spero from this offering are $75,000,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Spero. All of the shares in the offering will be sold by Spero. In addition, Spero has granted the underwriters a 30-day option to purchase up to an additional 567,000 shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on July 17, 2018, subject to customary closing conditions. |
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR), bacterial infections. Co.'s product candidate, SPR994 (tebipenem pivoxil hydrobromide), is designed to be oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Co. also has a platform technology known as its Potentiator Platform, which includes two intravenous-administered agents, SPR206 and SPR741, that are active either alone or in combination with other standard of care agents and are designed to treat MDR Gram-negative bacteria in the hospital.
 Open the SPRO Page at Preferred Stock Channel »
Open the SPRO Page at Preferred Stock Channel (in a new window) »
|
|
